Search

Displaying results 5161 - 5170 of 7540 in total
  1. Drug

    Fluticasone furoate

    go.drugbank.com/drugs/DB08906
    ApprovedInvestigational

    Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label] . Fluticasone furoate was first approved in 2007 .

    Categories: Agents to Treat Airway Disease
  2. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Iodoquinol is not currently available in any FDA-approved products.

  3. Drug

    Onapristone

    go.drugbank.com/drugs/DB12637
    Investigational

    treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no

  4. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  5. Drug

    Mizacorat

    go.drugbank.com/drugs/DB21458
    Investigational

    Mizacorat is under investigation in clinical trial NCT04556760 (Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 Diabetes

  6. Drug

    Seliciclib

    go.drugbank.com/drugs/DB06195
    Investigational

    Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation

  7. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  8. Drug

    INCB-9471

    go.drugbank.com/drugs/DB12960
    Investigational

    INCB-9471 is a novel, orally available CCR5 antagonist that is part of a new class of drugs to treat HIV/AIDS. It is a potent, selective inhibitor of the HIV-1 virus.

  9. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

  10. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    However, being on the controlled drug and substance act does not necessitate that the drug is approved for sale on the market. … Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug.